European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations

The overall objective of these guidelines is to provide evidence-based recommendations for the diagnosis and management of immunoglobulin G4 (IgG4)-related digestive disease in adults and children. IgG4-related digestive disease can be diagnosed only with a comprehensive work-up that includes histol...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: J-Matthias Löhr
Beuers Ulrich
Vujasinovic Miroslav
Alvaro Domenico
Párniczky Andrea
Frokjaer Jens Brondum
Buttgereit Frank
Capurso Gabriele
Culver Emma L.
De-Madaria Enrique
Della-Torre Emanuel
Detlefsen Sonke
Czakó László
Hegyi Péter
UEG guideline working group
Dokumentumtípus: Cikk
Megjelent: 2020
Sorozat:UNITED EUROPEAN GASTROENTEROLOGY JOURNAL 8 No. 6
doi:10.1177/2050640620934911

mtmt:31355961
Online Access:http://publicatio.bibl.u-szeged.hu/21994
Leíró adatok
Tartalmi kivonat:The overall objective of these guidelines is to provide evidence-based recommendations for the diagnosis and management of immunoglobulin G4 (IgG4)-related digestive disease in adults and children. IgG4-related digestive disease can be diagnosed only with a comprehensive work-up that includes histology, organ morphology at imaging, serology, search for other organ involvement, and response to glucocorticoid treatment. Indications for treatment are symptomatic patients with obstructive jaundice, abdominal pain, posterior pancreatic pain, and involvement of extra-pancreatic digestive organs, including IgG4-related cholangitis. Treatment with glucocorticoids should be weight-based and initiated at a dose of 0.6-0.8 mg/kg body weight/day orally (typical starting dose 30-40 mg/day prednisone equivalent) for 1 month to induce remission and then be tapered within two additional months. Response to initial treatment should be assessed at week 2-4 with clinical, biochemical and morphological markers. Maintenance treatment with glucocorticoids should be considered in multi-organ disease or history of relapse. If there is no change in disease activity and burden within 3 months, the diagnosis should be reconsidered. If the disease relapsed during the 3 months of treatment, immunosuppressive drugs should be added.
Terjedelem/Fizikai jellemzők:637-666
ISSN:2050-6406